Skip to main content

Nicolás Miguel Fissolo

I am biochemist and PhD in human biology. Since 2008 I work as a researcher at the clinical neuroimmunology - Multiple Sclerosis Center of Catalonia (Cemcat) research group. My activity is based on the study of multiple sclerosis, mainly in the identification of molecular biomarkers associated to different aspects of the disease.

Institutions of which they are part

Main researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca
Investigador/a postdoctoral
Multiple Sclerosis Centre of Catalonia

Nicolás Miguel Fissolo

Institutions of which they are part

Main researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca
Investigador/a postdoctoral
Multiple Sclerosis Centre of Catalonia

I am biochemist and PhD in human biology. Since 2008 I work as a researcher at the clinical neuroimmunology - Multiple Sclerosis Center of Catalonia (Cemcat) research group. My activity is based on the study of multiple sclerosis, mainly in the identification of molecular biomarkers associated to different aspects of the disease.

I graduated as a biochemist in 1999 from the University of Córdoba (Argentina). In 2005 I obtained a PhD in human biology from the University of Ulm (Germany) for my work in the DNA vaccine field. Afterwards, I carried out a 3-year postdoctoral stay at the Hertie Institut for Brain Research at the University of Tübingen (Germany) focused on the study of antigenic presentation in multiple sclerosis. In 2008 I joined the research group of the clinical neuroimmunology - Cemcat directed by Dr. Xavier Montalban where I have been working until now.

Since 2010 I have been working as principal investigator of several projects focused on the identification of new molecular biomarkers that allow the characterization of the different aspects of the disease, among which are included prognostic biomarkers in the initial phases of the disease, biomarkers of response to treatment, and biomarkers of disease activity.

Projects

REEM - Red Española de Esclerosis Múltiple

IP: REEM - Red Española de Esclerosis Múltiple
Collaborators: Carlos Nos Llopis, REEM - Red Española de Esclerosis Múltiple, Jaume Sastre Garriga, Jordi Rio Izquierdo, Fco. Javier Aymerich Martínez, Ingrid Galán Cartaña, Rosalia Horno Ocaña, Manuel Comabella Lopez, Carmen Tur Gomez, Herena Eixarch Ahufinger, Montserrat Moreno Sánchez, Alex Rovira Cañellas, REEM - Red Española de Esclerosis Múltiple, M Jesus Arevalo Navines, Dunia Muñoz Valdivielso, Carmen Espejo Ruiz, Angela Vidal Jordana, Joaquin Castillo Justribo, Mireia Castillo Juarez, Nicolás Miguel Fissolo
Funding agency: Instituto de Salud Carlos III
Funding: 364373.77
Reference: RD07/0060/0020
Duration: 01/01/2008 - 31/12/2014

Related news

An international study led by researchers from Vall d’Hebron shows that simple tests that patients can perform themselves help detect changes in disability that may occur even in the absence of disease relapses.

A Vall d’Hebron study, carried out at Cemcat, shows that the risk of inflammatory activity increases after discontinuing treatment, but is considerably reduced in people over 60 years of age.

The project will analyse the functional activation of the NLRP3 inflammasome to advance the early identification of patients at risk of insufficient response to S1P receptor-modulating therapies.

Related professionals

Berta Mercader Alegre

Berta Mercader Alegre

Research technician
Physical Medicine and Rehabilitation
Read more
Tatiana Murillo Fontana

Tatiana Murillo Fontana

Research technician
Systemic Diseases
Read more
Miguel Nuño Perez

Miguel Nuño Perez

Predoctoral researcher
Reconstructive Surgery of the Locomotor System
Read more
Yuri Lara Taranchenko

Yuri Lara Taranchenko

Predoctoral researcher
Reconstructive Surgery of the Locomotor System
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.